Exelixis Clinical Site #140

Porto Alegre, Rio Grande do Sul 90110-270

0 studies enrolling now · 2 studies all time

What they study most

Differentiated Thyroid Cancer, Renal Cell Carcinoma

Studies at this site

• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy — Running, not enrolling
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — Running, not enrolling